What's new

  • Maccabi Healthcare Services (MHS) Hypertension Registry (Israel);
  • IMS Real-World Data Adjudicated Claims Database (Canada);
  • Maccabi Healthcare Services (MHS) Osteoporosis Registry (Israel);

We now have 255 profiles in our collection – from 35 countries!

For those attending ICPE in Boston: Stop by Booth #7 for demos and surprises!

Come visit DGI at ICPE in Boston (August 24-26, 2015 - Booth #7). We are getting everything ready - from our poster titled "Toward Optimizing Data Structures in Cancer Registries" (Abstract #978) to personalized Demos and Surprises for those who stop by. View our latest newsletter for the event.

We have reached a milestone with the addition of Nigerian National System of Cancer Registries (NSCR) as our 250th profile!! Thank you to all the database managers for helping us review and edit their respective profiles over the years, and thank you to all those who have used our resource and helped us get this far.

In honor of this milestone we are offering 20% off our current global subscriptions*, and 15% off all other subscription rates*. Offer valid until July 31, 2015.

The Anolinx Active Patient Network (AAPN) consists of multiple databases housed at several healthcare institutions across the country as well as a large pre-claims database that Anolinx houses internally on its own servers. AAPN consists of inpatient and outpatient data from a multi-institutional network that includes more than 1500 hospitals and clinics across all 50 states and U.S. territories. These include government, academic, and private institutions. An approximate total of 90 million patients are in the AAPN, with about 20 million patients actively registered.

Interested in knowing the type of information subscribers have access to? We have updated our sample set of 5 profiles on B.R.I.D.G.E. TO DATA to give you a glimpse into how each database is described. Each of the 75 database fields is complete with information to aid you in finding the correct database for your needs.

View a map of all our database profiles worldwide.

We are excited to include the Programme de Médicalisation des Systèmes d'Information (PMSI; French Medico-administrative Database) as our 248th database profile. PMSI is the French system of case-mixed classification for hospital management. A standardized medical outcome summary from each hospital stay contains administrative and clinical data. PMSI combines data from medical, surgery, obstetric, odontology, and psychiatric centers as well as long-term care facilities and at-home hospitalizations.

Maccabi Healthcare Services (MHS) Chronic Kidney Disease (CKD) Registry is our newest database profile and the fifth from Israel.

The CKD Registry was initiated in 2001. As of April 2015, 139,000 members have been registered, of which 99,919 are currently active.

The following disease categories are included: Glomerular Filtration Rate, Proteinuria (for early stage), Dialysis, Kidney transplant. Read more about it by logging into our resource.

For a map listing our 247 databases from 34 countries click here.

In our ongoing effort to expand B.R.I.D.G.E., we now have profiles from 34 countries, with our latest addition being from Mexico – seriously! RENASICA is a prospective, multicenter, observational registry of acute coronary syndrome cases in Mexico with 1 year of follow-up. RENASICA is on its third iteration, and contains diagnosis, prescription drug, and laboratory data on over 8,000 patients.

  • CSD Longitudinal Population Database: Belgium. The CSD LPD Belgian DB began collecting data in 2005 and includes outpatient EMR data on 1.7 Million patients from different parts of Belgium. The database includes diagnoses, procedure and prescription drug data. While these data are not accessible by researchers, CSD can perform data analyses based on requests.

The IMS® Oncology Analyzer (Taiwan) is the second in a series of IMS® Oncology Analyzer databases we are adding to our resource. Potential uses of this database include help with: (1) Determining patient segmentation and targeting based on actual clinical practice; (2) Sizing the market accurately to assess brand potential; (3) Monitoring brand performance, new product uptake and therapy adoption globally; (4) Evaluating treatment flows from diagnosis to current therapy; and (5) Benchmarking against competitor performance.